NL7906835A - Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan. - Google Patents
Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan. Download PDFInfo
- Publication number
- NL7906835A NL7906835A NL7906835A NL7906835A NL7906835A NL 7906835 A NL7906835 A NL 7906835A NL 7906835 A NL7906835 A NL 7906835A NL 7906835 A NL7906835 A NL 7906835A NL 7906835 A NL7906835 A NL 7906835A
- Authority
- NL
- Netherlands
- Prior art keywords
- etomidate
- infusion liquid
- intravenous administration
- solution
- physiologically acceptable
- Prior art date
Links
- 239000003978 infusion fluid Substances 0.000 title claims description 34
- 238000001990 intravenous administration Methods 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 10
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 43
- 229960001690 etomidate Drugs 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- NCDXBSVHIGDPOE-RFVHGSKJSA-N ethyl 3-[(1r)-1-phenylethyl]imidazole-4-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NCDXBSVHIGDPOE-RFVHGSKJSA-N 0.000 claims description 13
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YCUUCSZGTWIJDW-RFVHGSKJSA-N ethyl 3-[(1r)-1-phenylethyl]imidazole-4-carboxylate;sulfuric acid Chemical compound OS(O)(=O)=O.CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 YCUUCSZGTWIJDW-RFVHGSKJSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94223678A | 1978-09-14 | 1978-09-14 | |
| US94223678 | 1978-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL7906835A true NL7906835A (nl) | 1980-03-18 |
Family
ID=25477775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7906835A NL7906835A (nl) | 1978-09-14 | 1979-09-13 | Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4289783A (cs) |
| JP (1) | JPS5547858A (cs) |
| BE (1) | BE878709A (cs) |
| CA (1) | CA1140048A (cs) |
| CH (1) | CH651752A5 (cs) |
| CY (1) | CY1254A (cs) |
| DE (1) | DE2937290A1 (cs) |
| DK (1) | DK154926C (cs) |
| ES (1) | ES484160A1 (cs) |
| FR (1) | FR2435945A1 (cs) |
| GB (1) | GB2029700B (cs) |
| GR (1) | GR64915B (cs) |
| HK (1) | HK80984A (cs) |
| HU (1) | HU179989B (cs) |
| IE (1) | IE48689B1 (cs) |
| IT (1) | IT1120537B (cs) |
| KE (1) | KE3426A (cs) |
| NL (1) | NL7906835A (cs) |
| SE (1) | SE447961B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225045A (en) * | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| WO2008112641A2 (en) * | 2007-03-09 | 2008-09-18 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
| AU2008340865B2 (en) | 2007-12-20 | 2014-01-23 | Acarix A/S | An adhesive patch for monitoring acoustic signals |
| EP3210976A1 (en) | 2008-03-31 | 2017-08-30 | The General Hospital Corporation | Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties |
| BR112012000606A2 (pt) | 2009-07-10 | 2016-11-22 | Brigham & Womens Hospital | análogos de etomidato que não inibem a síntese de esteróides adrenocorticais |
| EA027976B1 (ru) | 2012-01-13 | 2017-09-29 | Дзе Дженерал Хоспитал Корпорейшн | Анестезирующие соединения и способы их применения |
| US20180022698A1 (en) | 2014-10-16 | 2018-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354173A (en) * | 1964-04-16 | 1967-11-21 | Janssen Pharmaceutica Nv | Imidazole carboxylates |
-
1979
- 1979-07-23 GR GR59677A patent/GR64915B/el unknown
- 1979-07-27 CY CY1254A patent/CY1254A/en unknown
- 1979-07-27 GB GB7926364A patent/GB2029700B/en not_active Expired
- 1979-08-23 IT IT50093/79A patent/IT1120537B/it active
- 1979-09-05 CA CA000335043A patent/CA1140048A/en not_active Expired
- 1979-09-05 FR FR7922235A patent/FR2435945A1/fr active Granted
- 1979-09-11 BE BE0/197088A patent/BE878709A/nl not_active IP Right Cessation
- 1979-09-11 JP JP11579179A patent/JPS5547858A/ja active Granted
- 1979-09-13 DK DK384379A patent/DK154926C/da not_active IP Right Cessation
- 1979-09-13 ES ES484160A patent/ES484160A1/es not_active Expired
- 1979-09-13 SE SE7907621A patent/SE447961B/sv not_active IP Right Cessation
- 1979-09-13 HU HU79JA855A patent/HU179989B/hu not_active IP Right Cessation
- 1979-09-13 NL NL7906835A patent/NL7906835A/nl not_active Application Discontinuation
- 1979-09-13 IE IE1741/79A patent/IE48689B1/en not_active IP Right Cessation
- 1979-09-14 CH CH8358/79A patent/CH651752A5/de not_active IP Right Cessation
- 1979-09-14 DE DE19792937290 patent/DE2937290A1/de not_active Ceased
-
1980
- 1980-01-16 US US06/112,671 patent/US4289783A/en not_active Expired - Lifetime
-
1984
- 1984-07-20 KE KE3426A patent/KE3426A/xx unknown
- 1984-11-25 HK HK809/84A patent/HK80984A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK154926C (da) | 1989-05-29 |
| GB2029700B (en) | 1983-03-30 |
| US4289783A (en) | 1981-09-15 |
| JPH0214058B2 (cs) | 1990-04-06 |
| CY1254A (en) | 1984-08-31 |
| GR64915B (en) | 1980-06-09 |
| KE3426A (en) | 1984-08-10 |
| DK384379A (da) | 1980-03-15 |
| DK154926B (da) | 1989-01-09 |
| IE48689B1 (en) | 1985-04-17 |
| DE2937290A1 (de) | 1980-04-03 |
| IT7950093A0 (it) | 1979-08-23 |
| FR2435945A1 (fr) | 1980-04-11 |
| HU179989B (en) | 1983-01-28 |
| FR2435945B1 (cs) | 1983-02-25 |
| HK80984A (en) | 1984-11-25 |
| ES484160A1 (es) | 1980-10-01 |
| BE878709A (nl) | 1980-03-11 |
| IE791741L (en) | 1980-03-14 |
| CH651752A5 (de) | 1985-10-15 |
| SE447961B (sv) | 1987-01-12 |
| SE7907621L (sv) | 1980-03-15 |
| CA1140048A (en) | 1983-01-25 |
| IT1120537B (it) | 1986-03-26 |
| JPS5547858A (en) | 1980-04-05 |
| GB2029700A (en) | 1980-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100505772B1 (ko) | 개선된정맥투여용농축주사액및주입액 | |
| JP5555425B2 (ja) | 薬剤復元または希釈のための塩化ナトリウム溶液 | |
| JP2003502363A (ja) | プロポフォールを含有する静脈内注射用麻酔剤組成物 | |
| JPS59167512A (ja) | ニモジピン液体組成物 | |
| KR19980033113A (ko) | 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법 | |
| US7423028B2 (en) | Injectable pharmaceutical compositions comprising sodium diclofenac and β-cyclodextrin | |
| WO2004032910A1 (en) | Injectable 2,6-diisopropylphenol-containing anesthetic composition and methods | |
| NL7906835A (nl) | Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan. | |
| US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
| JP2822058B2 (ja) | 安定な点眼剤 | |
| TW527190B (en) | Pharmaceutical composition for treating acute renal failure caused by rhabdomyolysis, and for treating myoglobinuria | |
| US4696814A (en) | Parenteral phenytoin compositions | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| CN1756541A (zh) | 包含5－甲基－2－(2′－氯－6′－氟苯氨基)苯乙酸的药物组合物 | |
| CN113197848B (zh) | 一种重酒石酸间羟胺药物组合物及其制备方法 | |
| JP2015506381A (ja) | デオキシコール酸ナトリウムを含有しないホスファチジルコリン含有注射剤組成物及びこれの製造方法（Ｉｎｊｅｃｔａｂｌｅｃｏｍｐｏｓｉｔｉｏｎｏｆｐｈｏｓｐｈａｔｉｄｙｌｃｈｏｌｉｎｅｄｅｖｏｉｄｏｆｓｏｄｉｕｍｄｅｏｘｙｃｈｏｌａｔｅａｎｄｍａｎｕｆａｃｔｕｒｉｎｇｍｅｔｈｏｄｔｈｅｒｅｏｆ） | |
| JP2946015B2 (ja) | 安定な抗ウィルス点滴用注射剤 | |
| KR830000526B1 (ko) | 에토 미데이트를 함유한 주사제의 제조방법 | |
| AU2003241800B2 (en) | Pharmaceutical composition | |
| JPH07316065A (ja) | Ｆｒ９０１４６９物質製剤 | |
| JPS6340166B2 (cs) | ||
| Duncan et al. | Effect of hyperuricemia on renal function in the dog | |
| EP0639376A1 (en) | Liquid composition containing amide derivative | |
| JPH0543462A (ja) | ピペラジン誘導体を含有する注射剤 | |
| JPS6133127A (ja) | 医薬活性化合物の包接化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |